Medwave (May 2021)

Effects of ulipristal acetate in patients with symptomatic uterine fibroids

  • Natalia Navarro Plazaola,
  • Marla Vega Chacana,
  • Raimundo Avilés Dorlhiac

DOI
https://doi.org/10.5867/medwave.2021.04.8162
Journal volume & issue
Vol. 21, no. 04
pp. e8162 – e8162

Abstract

Read online

Introduction Uterine fibroids are frequently encountered in gynecology and are a therapeutic challenge. New therapies, such as ulipristal acetate, could help with symptomatic relief, improve quality of life, and decrease uterine fibroid size. Notwithstanding, there is controversy about adverse effects, especially for hepatotoxicity. Methods We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis, and generated a summary of findings table using the GRADE approach. Results and conclusions We identified nine systematic reviews and included ten studies overall, of which five were randomized trials. We conclude that ulipristal increases the likelihood of amenorrhea, improves the quality of life, and decreases menstrual bleeding. However, there is also a likely

Keywords